PubRank

David Pfister

Author PubWeight™ 44.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010 3.11
2 Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2009 2.40
3 Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2008 2.34
4 The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr 2009 2.16
5 Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2005 2.04
6 Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007 1.91
7 Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2008 1.69
8 Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2012 1.69
9 Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. BJU Int 2011 1.56
10 Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2009 1.53
11 Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 2011 1.52
12 Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010 1.52
13 Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012 1.40
14 Surgical resection of urological tumor metastases following medical treatment. Dtsch Arztebl Int 2012 1.34
15 Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer 2002 1.26
16 Near-infrared spectroscopy can monitor dynamic cerebral autoregulation in adults. Neurocrit Care 2008 1.23
17 Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012 1.16
18 Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol 2013 1.01
19 A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol 2011 0.93
20 Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Ther Adv Urol 2012 0.93
21 Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 2010 0.93
22 Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002 0.93
23 Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. J Clin Oncol 2007 0.86
24 Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004 0.86
25 No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patients. Med Microbiol Immunol 2011 0.80
26 Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethra. Radiother Oncol 2012 0.79
27 Role of Focal Therapy with High-Intensity Focused Ultrasound in the Management of Clinically Localized Prostate Cancer. Oncol Res Treat 2015 0.79
28 Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure. BMC Genet 2002 0.78
29 Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer 2011 0.78
30 A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2010 0.78
31 Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasia. Clin Biochem 2011 0.77
32 Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol 2013 0.76
33 Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy. Arch Esp Urol 2012 0.75
34 Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol 2012 0.75
35 Prostate cancer: in favour of active surveillance--functional outcomes matter. Nat Rev Urol 2013 0.75
36 [Hypogonadism - testosterone replacement therapy after prostate cancer?]. Aktuelle Urol 2014 0.75
37 The Role of Palliative Surgery in Castration-Resistant Prostate Cancer. Oncol Res Treat 2015 0.75
38 Strong [(68)Ga]PSMA-HBED-CC accumulation in non-cancerous prostate tissue surrounding a PSMA-negative prostate carcinoma recurrence. Nuklearmedizin 2016 0.75
39 HIV-Associated Urogenital Malignancies. Oncol Res Treat 2017 0.75
40 PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [(68)Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer. Nuklearmedizin 2017 0.75
41 Do alpha-reductase inhibitors prevent prostate cancer? 2008 practice guideline from the American society of clinical oncology and American urological association. Pol Arch Med Wewn 2009 0.75
42 Sextant-Specific Analysis of Detection and Tumor Volume by HistoScanning™. Urol Int 2015 0.75
43 The role of palliative surgery in castration-resistant prostate cancer. Curr Opin Support Palliat Care 2014 0.75
44 Metastasiertes kastrationsresistentes Prostatakarzinom: Grundsätzliche Therapieoptionen und Progression. Oncol Res Treat 2017 0.75
45 Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer. Urol Int 2017 0.75